4.5 Editorial Material

Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Polypharmacy Among Headache Patients: A Cross-Sectional Study

Anna Ferrari et al.

CNS DRUGS (2018)

Review Clinical Neurology

Is Migraine Primarily a Metaboloendocrine Disorder?

Innocenzo Rainero et al.

CURRENT PAIN AND HEADACHE REPORTS (2018)

Editorial Material Clinical Neurology

Migraine is first cause of disability in under 50s: will health politicians now take notice?

Timothy J. Steiner et al.

JOURNAL OF HEADACHE AND PAIN (2018)

Article Clinical Neurology

The epidemiology of headache disorders: a face-to-face interview of participants in HUNT4

Knut Hagen et al.

JOURNAL OF HEADACHE AND PAIN (2018)

Article Clinical Neurology

Psychiatric comorbidities and photophobia in patients with migraine

Stefan Seidel et al.

JOURNAL OF HEADACHE AND PAIN (2017)

Article Clinical Neurology

Migraine and Cerebrovascular Atherosclerosis in Patients With Ischemic Stroke

Hendrikus J. A. van Os et al.

STROKE (2017)

Review Biochemistry & Molecular Biology

Personalised Healthcare: The DiMA Clinical Model

Marina Borro et al.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2017)

Review Biochemistry & Molecular Biology

Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations

Luana Lionetto et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)

Review Pharmacology & Pharmacy

Pharmacogenetic insights into migraine treatment in children

Giovanna Gentile et al.

PHARMACOGENOMICS (2014)

Review Clinical Neurology

The omics in migraine

Luana Lionetto et al.

JOURNAL OF HEADACHE AND PAIN (2013)

Article Biochemistry & Molecular Biology

DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs

Craig Knox et al.

NUCLEIC ACIDS RESEARCH (2011)

Article Pharmacology & Pharmacy

The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes

Bent H. Hellum et al.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2007)

Article Integrative & Complementary Medicine

Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome p450 3A4, 2D6, and 2C9

SH Yale et al.

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (2005)

Article Biotechnology & Applied Microbiology

Pharmacogenetics and herb-drug interactions:: experience with Ginkgo biloba and omeprazole

OQP Yin et al.

PHARMACOGENETICS (2004)

Article Medicine, General & Internal

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients

M Pirmohamed et al.

BMJ-BRITISH MEDICAL JOURNAL (2004)

Article Biochemistry & Molecular Biology

Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract

C Gaudineau et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)

Article Pharmacology & Pharmacy

The influence of St. John's wort on CYP2C19 activity with respect to genotype

LS Wang et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2004)

Article Pharmacology & Pharmacy

Saint John's wort:: An in vitro analysis of P-glycoprotein induction due to extended exposure

MD Perloff et al.

BRITISH JOURNAL OF PHARMACOLOGY (2001)